Fibroscan测定联合血清学指标在检测肝硬化患者门静脉血流动力学指标中的应用价值

Application value of Fibroscan detection combined with serological indicator in detection of portal venous hemodynamics indicator for patient with liver cirrhosis

目的分析Fibroscan测定联合血清学指标在检测肝硬化患者门静脉血流动力学指标中的应用价值。方法 40例肝硬化患者作为研究组,同期40例健康体检者作为对照组。比较两组Fibroscan值、血清学指标[透明质酸(HA)、Ⅳ型胶原(C-Ⅳ)、Ⅲ型前胶原(PCⅢ)]变化情况及门静脉血流动力学指标(门静脉内径、门静脉流速)变化情况。结果研究组Fibroscan值、HA、C-Ⅳ、PCⅢ均高于对照组,差异均有统计学意义(t=3.745、22.928、18.206、8.932,P<0.05)。研究组门静脉内径为(1.27±0.06)cm,门静脉流速为(14.46±1.95)cm/s;对照组门静脉内径为(1.15±0.05)cm,门静脉流速为(17.78±1.26)cm/s,研究组门静脉内径大于对照组,门静脉流速低于对照组,差异均有统计学意义(P<0.05)。结论 Fibroscan测定联合血清学指标可有效检测肝硬化患者门静脉血流动力学指标变化情况,具有推广价值。

Objective To analyze application value of Fibroscan detection combined with serological indicator in detection of portal venous hemodynamics indicator for patient with liver cirrhosis. Methods There were 40 liver cirrhosis patients as research group, and concurrent 40 healthy examination people as control group. Comparison were made on Fibroscan value, serological indicator changes [hyaluronic acid（HA）, type Ⅳ collagen（C-Ⅳ）, type Ⅲ pro-collagen（PCⅢ）] and changes of portal venous hemodynamics indicator（partal vein diameter and portal vein velocity） in two groups. Results The research group had higher Fibroscan value, HA, C-Ⅳ and PC Ⅲ than those in the control group（t=3.745, 22.928, 18.206 and 8.932, P〈0.05）. The research group had partal vein diameter as（1.27±0.06） cm, portal vein velocity as（14.46±1.95） cm/s, while（1.15±0.05） cm and（17.78±1.26） cm/s in the control group. The research group had larger partal vein diameter than the control group, lower portal vein velocity than the control group. All differences had statistical significance（P〈0.05）. Conclusion Fibroscan detection combined with serological indicator can effectively detect changes of portal venous hemodynamics indicator for patient with liver cirrhosis. This method contains promotional value.